Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a
provider of innovative spine surgery solutions dedicated to
revolutionizing the approach to spine surgery, today announced
financial results for the quarter ended June 30, 2019, and recent
corporate highlights.
Second Quarter 2019 Financial
Highlights
- Total net revenue of $27.3 million; U.S. revenue
of $26.1 million, up approximately 28% compared to the second
quarter of 2018;
- U.S. gross margin of 72.2%; and
- Cash and cash equivalents of $18.6 million as
of June 30, 2019.
Second Quarter-to-Date Commercial,
Product, and Organizational Highlights
- Enhanced clinical distinction of portfolio with four new
commercial releases: the IdentiTi™ TLIF system, the IdentiTi
ALIF system, the InVictus™ MIS Fixation System and the
InVictus Open Fixation System;
- Increased contribution from new products to 32% of Q2 2019 U.S.
revenue;
- Expanded percentage of revenue driven by strategic distribution
network to 88% of U.S. revenue in Q2 2019 compared to 80% in Q2
2018; and
- Increased U.S. revenue per distributor by more than 45% and
increased U.S. revenue per case by 15% in Q2 2019 compared to Q2
2018.
“Through the first half of 2019, execution
against our strategic commitments has been solid,” said Pat Miles,
Chairman and Chief Executive Officer. “That execution drove
the highest rate of quarterly U.S. revenue growth this company has
achieved in the past 10 years. Based upon our performance in
the first half of 2019 we are increasing full-year revenue
guidance, which speaks to the impact of spine’s new Organic
Innovation Machine. We are just getting started.”
Comparison of Selected GAAP and Non-GAAP
Financial Results for the Second Quarter 2019 to Second Quarter
2018
|
Three Months Ended |
|
Change |
|
June 30, 2019 |
|
June 30, 2018 |
|
$ |
|
% |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from U.S. products |
$ |
26,093 |
|
|
$ |
20,409 |
|
|
$ |
5,684 |
|
|
28 |
% |
Gross profit from U.S.
products |
|
18,841 |
|
|
|
15,462 |
|
|
|
3,379 |
|
|
22 |
% |
Gross margin from U.S.
products |
|
72.2 |
% |
|
|
75.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
Research and development |
$ |
3,360 |
|
|
$ |
2,009 |
|
|
$ |
1,351 |
|
|
67 |
% |
Sales, general and administrative |
|
24,568 |
|
|
|
17,538 |
|
|
|
7,030 |
|
|
40 |
% |
Litigation-related expenses |
|
1,200 |
|
|
|
2,234 |
|
|
|
(1,034 |
) |
|
(46 |
%) |
Amortization of intangible assets |
|
172 |
|
|
|
187 |
|
|
|
(15 |
) |
|
(8 |
%) |
Transaction-related expenses |
|
- |
|
|
|
(62 |
) |
|
|
62 |
|
|
(100 |
%) |
Restructuring |
|
- |
|
|
|
193 |
|
|
|
(193 |
) |
|
(100 |
%) |
Total operating expenses |
$ |
29,300 |
|
|
$ |
22,099 |
|
|
$ |
7,201 |
|
|
33 |
% |
|
|
|
|
|
|
|
|
Operating loss |
$ |
(10,414 |
) |
|
$ |
(6,545 |
) |
|
$ |
(3,869 |
) |
|
59 |
% |
|
|
|
|
|
|
|
|
Non-GAAP operating loss |
$ |
(4,663 |
) |
|
$ |
(2,578 |
) |
|
$ |
(2,085 |
) |
|
81 |
% |
|
|
|
|
|
|
|
|
Non-GAAP adjusted EBITDA |
$ |
(3,018 |
) |
|
$ |
(989 |
) |
|
$ |
(2,029 |
) |
|
205 |
% |
Revenue from U.S. products for the second
quarter 2019 was $26.1 million, up 28% compared to $20.4 million in
the second quarter 2018. Revenue growth generated by new product
momentum and the strategic distribution channel is increasingly
outpacing the continued revenue impacts of transitioning or
discontinuing non-strategic distributor relationships.
Gross profit and gross margin from U.S. products
for the second quarter 2019 were $18.8 million and 72.2%,
respectively, compared to $15.5 million and 75.8%, respectively,
for the second quarter 2018. U.S. gross margin was impacted by
increased non-cash excess and obsolete write-offs related to legacy
products. On a non-GAAP basis, excluding non-cash excess and
obsolete charges, U.S. gross margin was 80.6% in the second quarter
of 2019, up from 77.5% in the second quarter of 2018.
Total operating expenses for the second quarter
2019 were $29.3 million compared to $22.1 million in the second
quarter 2018. On a non-GAAP basis, excluding restructuring
charges, stock-based compensation, transaction-related expenses,
litigation-related expenses, restructuring and fair value
adjustments, total operating expenses in the second quarter 2019
increased to $25.8 million from $18.5 million in 2018, reflecting
increased investments in organic product development to support new
product launches and increased selling costs from U.S. revenue
growth.
Non-GAAP operating loss which excludes
restructuring charges, stock-based compensation,
transaction-related expenses, litigation-related expenses,
restructuring, fair value adjustments and excess and obsolescence
charges, was $4.7 million for the second quarter 2019, compared to
a loss of $2.6 million for the second quarter 2018.
Non-GAAP adjusted EBITDA in the second quarter
was a loss of $3.0 million, compared to a loss of $1.0 million in
the second quarter 2018.
For more detailed information on non-GAAP
operating expenses, non-GAAP operating loss and non-GAAP adjusted
EBITDA, please refer to the table, “Alphatec Holdings, Inc.
Reconciliation of Non-GAAP Financial Measures,” that follows.
Current and long-term debt includes $45.0
million in term debt and $10.7 million outstanding under the
Company’s revolving credit facility at June 30, 2019, with cash and
cash equivalents of $18.6 million. In March 2019, the Company
closed its expanded credit facility with Squadron Medical Finance
Solutions, providing for up to $30 million in additional financing,
as needed. During the second quarter 2019, the Company drew $10
million against the credit facility.
Updated 2019 Financial
Outlook
Full Year 2019 |
Previous |
Updated |
|
Guidance ($M) |
YoY Growth |
Guidance ($M) |
YoY Growth |
U.S. Product Revenue |
$94 to $98 |
12% to 17% |
$100 to $104 |
20% to 24% |
International Supply Agreement |
$4 to $5 |
(38%) to (50%) |
No change |
No change |
Total Revenue |
$98 to $103 |
7% to 12% |
$104 to $109 |
13% to 19% |
Investor Conference Call
ATEC will present the results via a live webcast
today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At
that time, please click here to access the live webcast. An
audiocast of the presentation will be also be available
domestically at (877) 556-5251 and internationally at (720)
545-0036. The conference ID number is 6098197.
Non-GAAP Financial
Information
To supplement the Company’s financial statements
presented in accordance with U.S. generally accepted accounting
principles (GAAP), the Company reports certain non-GAAP financial
measures, including non-GAAP U.S. gross margin, non-GAAP operating
expenses, non-GAAP operating loss, and non-GAAP adjusted
EBITDA. The Company believes that these non-GAAP financial
measures provide investors with an additional tool for evaluating
the Company's core performance, which management uses in its own
evaluation of continuing operating performance, and a baseline for
assessing the future earnings potential of the Company. The
Company’s non-GAAP financial measures may not provide information
that is directly comparable to that provided by other companies in
the Company’s industry, as other companies in the industry may
calculate non-GAAP financial results differently, particularly
related to non-recurring, unusual items. Non-GAAP financial results
should be considered in addition to, and not as a substitute for,
or superior to, financial measures calculated in accordance with
GAAP. Included below are reconciliations of the non-GAAP financial
measures to the comparable GAAP financial measures.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its
wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp
Surgical, Inc., is a provider of innovative spine surgery solutions
dedicated to revolutionizing the approach to spine surgery. ATEC
designs, develops and markets spinal fusion technology products and
solutions for the treatment of spinal disorders associated with
disease and degeneration, congenital deformities and trauma.
The Company markets its products in the U.S. via independent sales
agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to the
Company’s revenue and growth outlook, planned commercial launches
and product introductions, the Company’s strategy in significantly
repositioning the ATEC brand, turning the Company into a growth
organization and creating future market disruption, and the
Company’s future ability to finance its operations. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the
uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community; failure to obtain FDA or other
regulatory clearance or approval for new products, or unexpected or
prolonged delays in the process; continuation of favorable third
party reimbursement for procedures performed using the Company’s
products; unanticipated expenses or liabilities or other adverse
events affecting cash flow or the Company’s ability to successfully
control its costs or achieve profitability; uncertainty of
additional funding; the Company’s ability to compete with other
products and with emerging new technologies; product liability
exposure; an unsuccessful outcome in any litigation in which the
Company is a defendant; patent infringement claims; claims related
to the Company’s intellectual property and the Company’s ability to
meet its financial obligations under its credit agreements and
the OrthoTec LLC settlement agreement. The words “believe,”
“will,” “should,” “expect,” “intend,” “estimate,” “look forward”
and “anticipate,” variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. A
further list and description of these and other factors, risks and
uncertainties can be found in the Company's most recent annual
report, and any subsequent quarterly and current reports, filed
with the Securities and Exchange Commission. ATEC disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
Investor/Media Contact:
Tina JacobsenInvestor Relations(760)
494-6790ir@atecspine.com
Company Contact:
Jeff Black Chief Financial Officer ir@atecspine.com
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
|
|
|
|
|
Revenue from U.S. products |
$ |
26,093 |
|
|
$ |
20,409 |
|
|
$ |
49,048 |
|
|
$ |
39,610 |
|
|
|
Revenue from international supply agreement |
|
1,226 |
|
|
|
1,633 |
|
|
|
2,826 |
|
|
|
3,739 |
|
|
|
Total revenues |
|
27,319 |
|
|
|
22,042 |
|
|
|
51,874 |
|
|
|
43,349 |
|
|
|
Cost of revenues |
|
8,433 |
|
|
|
6,488 |
|
|
|
16,420 |
|
|
|
12,890 |
|
|
|
Gross profit |
|
18,886 |
|
|
|
15,554 |
|
|
|
35,454 |
|
|
|
30,459 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
3,360 |
|
|
|
2,009 |
|
|
|
6,829 |
|
|
|
3,795 |
|
|
|
Sales, general and administrative |
|
24,568 |
|
|
|
17,538 |
|
|
|
45,568 |
|
|
|
34,795 |
|
|
|
Litigation-related expenses |
|
1,200 |
|
|
|
2,234 |
|
|
|
3,823 |
|
|
|
2,814 |
|
|
|
Amortization of intangible assets |
|
172 |
|
|
|
187 |
|
|
|
354 |
|
|
|
364 |
|
|
|
Transaction-related expenses |
|
- |
|
|
|
(62 |
) |
|
|
- |
|
|
|
1,480 |
|
|
|
Gain on settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
|
|
Restructuring expenses |
|
- |
|
|
|
193 |
|
|
|
60 |
|
|
|
591 |
|
|
|
Total operating expenses |
|
29,300 |
|
|
|
22,099 |
|
|
|
56,634 |
|
|
|
37,671 |
|
|
|
Operating loss |
|
(10,414 |
) |
|
|
(6,545 |
) |
|
|
(21,180 |
) |
|
|
(7,212 |
) |
|
|
Total other expenses, net |
|
(1,921 |
) |
|
|
(1,784 |
) |
|
|
(4,040 |
) |
|
|
(3,429 |
) |
|
|
Loss from continuing
operations before taxes |
|
(12,335 |
) |
|
|
(8,329 |
) |
|
|
(25,220 |
) |
|
|
(10,641 |
) |
|
|
Income tax (benefit) provision |
|
71 |
|
|
|
(1,265 |
) |
|
|
102 |
|
|
|
(1,723 |
) |
|
|
Loss from continuing
operations |
|
(12,406 |
) |
|
|
(7,064 |
) |
|
|
(25,322 |
) |
|
|
(8,918 |
) |
|
|
Loss from discontinued operations |
|
(30 |
) |
|
|
(12 |
) |
|
|
(82 |
) |
|
|
(74 |
) |
|
|
Net loss |
$ |
(12,436 |
) |
|
$ |
(7,076 |
) |
|
$ |
(25,404 |
) |
|
$ |
(8,992 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share,
basic and diluted: |
|
|
|
|
|
|
|
|
|
Continuing operations |
$ |
(0.26 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.55 |
) |
|
$ |
(0.32 |
) |
|
|
Discontinued operations |
|
(0.00 |
) |
|
|
(0.00 |
) |
|
|
(0.00 |
) |
|
|
(0.00 |
) |
|
|
Net loss per share, basic and
diluted |
$ |
(0.27 |
) |
|
$ |
(0.21 |
) |
|
$ |
(0.55 |
) |
|
$ |
(0.33 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in calculating
basic and diluted net loss per share |
|
46,880 |
|
|
|
34,030 |
|
|
|
45,957 |
|
|
|
27,656 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation included in: |
|
|
|
|
|
|
|
|
|
Cost of revenue |
$ |
28 |
|
|
$ |
11 |
|
|
$ |
56 |
|
|
$ |
33 |
|
|
|
Research and development |
|
293 |
|
|
|
129 |
|
|
|
533 |
|
|
|
13 |
|
|
|
Sales, general and
administrative |
|
2,030 |
|
|
|
1,008 |
|
|
|
3,374 |
|
|
|
1,721 |
|
|
|
|
$ |
2,351 |
|
|
$ |
1,148 |
|
|
$ |
3,963 |
|
|
$ |
1,767 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
|
2019 |
|
2018 |
|
|
(Unaudited) |
|
|
|
ASSETS |
|
Current assets: |
|
|
|
|
Cash |
$ |
18,570 |
|
$ |
29,054 |
|
Accounts receivable, net |
|
13,642 |
|
|
15,095 |
|
Inventories, net |
|
32,605 |
|
|
28,765 |
|
Prepaid expenses and other current assets |
|
10,904 |
|
|
2,380 |
|
Current assets of discontinued operations |
|
225 |
|
|
242 |
|
Total current assets |
|
75,946 |
|
|
75,536 |
|
|
|
|
|
|
Property and equipment,
net |
|
15,090 |
|
|
13,235 |
|
Right-of-use asset |
|
2,170 |
|
|
- |
|
Goodwill |
|
13,897 |
|
|
13,897 |
|
Intangibles, net |
|
26,054 |
|
|
26,408 |
|
Other assets |
|
222 |
|
|
347 |
|
Noncurrent assets of
discontinued operations |
|
53 |
|
|
54 |
|
Total assets |
$ |
133,432 |
|
$ |
129,477 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ |
8,178 |
|
$ |
4,399 |
|
Accrued expenses |
|
20,831 |
|
|
22,316 |
|
Current portion of long-term debt |
|
286 |
|
|
3,276 |
|
Current portion of lease liability |
|
1,173 |
|
|
- |
|
Current liabilities of discontinued operations |
|
538 |
|
|
621 |
|
Total current liabilities |
|
31,006 |
|
|
30,612 |
|
|
|
|
|
|
Total long term liabilities |
|
64,662 |
|
|
57,688 |
|
|
|
|
|
|
Redeemable preferred stock |
|
23,603 |
|
|
23,603 |
|
Stockholders' equity |
|
14,161 |
|
|
17,574 |
|
Total liabilities and
stockholders' equity |
$ |
133,432 |
|
$ |
129,477 |
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
(in thousands - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
|
June 30, |
|
June 30, |
|
|
|
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
29,300 |
|
|
|
22,099 |
|
|
|
56,634 |
|
|
|
37,671 |
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
(2,323 |
) |
|
|
(1,137 |
) |
|
|
(3,907 |
) |
|
|
(1,734 |
) |
|
|
Contingent consideration fair value adjustment |
|
|
- |
|
|
|
(100 |
) |
|
|
(289 |
) |
|
|
(100 |
) |
|
|
Litigation-related expenses |
|
|
(1,200 |
) |
|
|
(2,234 |
) |
|
|
(3,823 |
) |
|
|
(2,814 |
) |
|
|
Restructuring |
|
|
- |
|
|
|
(193 |
) |
|
|
(60 |
) |
|
|
(591 |
) |
|
|
Transaction-related expenses |
|
|
- |
|
|
|
62 |
|
|
|
- |
|
|
|
(1,480 |
) |
|
|
Gain on settlement |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6,168 |
|
|
|
Non-GAAP operating
expenses |
|
$ |
25,777 |
|
|
$ |
18,497 |
|
|
$ |
48,555 |
|
|
$ |
37,120 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
|
June 30, |
|
June 30, |
|
|
|
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss, as
reported |
|
$ |
(10,414 |
) |
|
$ |
(6,545 |
) |
|
$ |
(21,180 |
) |
|
$ |
(7,212 |
) |
|
|
Add back significant
items: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
2,351 |
|
|
|
1,148 |
|
|
|
3,963 |
|
|
|
1,767 |
|
|
|
Contingent consideration fair value adjustment |
|
|
- |
|
|
|
100 |
|
|
|
289 |
|
|
|
100 |
|
|
|
Litigation-related expenses |
|
|
1,200 |
|
|
|
2,234 |
|
|
|
3,823 |
|
|
|
2,814 |
|
|
|
Restructuring |
|
|
- |
|
|
|
193 |
|
|
|
60 |
|
|
|
591 |
|
|
|
Transaction-related expenses |
|
|
- |
|
|
|
(62 |
) |
|
|
- |
|
|
|
1,480 |
|
|
|
Excess & obsolete charges |
|
|
2,200 |
|
|
|
354 |
|
|
|
4,175 |
|
|
|
1,272 |
|
|
|
Gain on settlement |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
|
|
Non-GAAP operating loss |
|
|
(4,663 |
) |
|
|
(2,578 |
) |
|
|
(8,870 |
) |
|
|
(5,356 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss, as
reported |
|
$ |
(10,414 |
) |
|
$ |
(6,545 |
) |
|
$ |
(21,180 |
) |
|
$ |
(7,212 |
) |
|
|
Depreciation |
|
|
1,473 |
|
|
|
1,457 |
|
|
|
3,076 |
|
|
|
3,049 |
|
|
|
Amortization of intangible assets |
|
|
172 |
|
|
|
132 |
|
|
|
354 |
|
|
|
426 |
|
|
|
EBITDA |
|
|
(8,769 |
) |
|
|
(4,956 |
) |
|
|
(17,750 |
) |
|
|
(3,737 |
) |
|
|
Add back significant
items: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
2,351 |
|
|
|
1,148 |
|
|
|
3,963 |
|
|
|
1,767 |
|
|
|
Contingent consideration fair value adjustment |
|
|
- |
|
|
|
100 |
|
|
|
289 |
|
|
|
100 |
|
|
|
Litigation-related expenses |
|
|
1,2a00 |
|
|
|
2,234 |
|
|
|
3,823 |
|
|
|
2,814 |
|
|
|
Restructuring |
|
|
- |
|
|
|
193 |
|
|
|
60 |
|
|
|
591 |
|
|
|
Transaction-related expenses |
|
|
- |
|
|
|
(62 |
) |
|
|
- |
|
|
|
1,480 |
|
|
|
Excess & obsolete charges |
|
|
2,200 |
|
|
|
354 |
|
|
|
4,175 |
|
|
|
1,272 |
|
|
|
Gain on settlement |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
|
|
Non-GAAP adjusted EBITDA |
|
$ |
(3,018 |
) |
|
$ |
(989 |
) |
|
$ |
(5,440 |
) |
|
$ |
(1,881 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS
PROFIT |
|
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
Revenues by source |
|
|
|
|
|
|
|
|
|
Revenue from U.S.
products |
$ |
26,093 |
|
|
$ |
20,409 |
|
|
$ |
49,048 |
|
|
$ |
39,610 |
|
|
|
Revenue from international
supply agreement |
|
1,226 |
|
|
|
1,633 |
|
|
|
2,826 |
|
|
|
3,739 |
|
|
|
Total revenues |
$ |
27,319 |
|
|
$ |
22,042 |
|
|
$ |
51,874 |
|
|
$ |
43,349 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit by source |
|
|
|
|
|
|
|
|
|
Revenue from U.S.
products |
$ |
18,841 |
|
|
$ |
15,462 |
|
|
$ |
35,235 |
|
|
$ |
30,229 |
|
|
|
Revenue from international
supply agreement |
|
45 |
|
|
|
92 |
|
|
|
219 |
|
|
|
230 |
|
|
|
Total gross profit |
$ |
18,886 |
|
|
$ |
15,554 |
|
|
$ |
35,454 |
|
|
$ |
30,459 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit margin by
source |
|
|
|
|
|
|
|
|
|
Revenue from U.S.
products |
|
72.2% |
|
|
|
75.8% |
|
|
|
71.8% |
|
|
|
76.3% |
|
|
|
Revenue from international
supply agreement |
|
3.7% |
|
|
|
5.6% |
|
|
|
7.7% |
|
|
|
6.2% |
|
|
|
Total gross profit margin |
|
69.1% |
|
|
|
70.6% |
|
|
|
68.3% |
|
|
|
70.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND GROSS
MARGIN FROM U.S. PRODUCTS |
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2019 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP-based gross profit from
U.S. products |
$ |
18,841 |
|
|
$ |
15,462 |
|
|
$ |
35,235 |
|
|
$ |
30,229 |
|
|
|
Add: non-cash excess and
obsolete charges |
|
2,200 |
|
|
|
354 |
|
|
|
4,175 |
|
|
|
1,272 |
|
|
|
Non-GAAP gross profit from
U.S. products |
$ |
21,041 |
|
|
$ |
15,816 |
|
|
$ |
39,410 |
|
|
$ |
31,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP-based gross margin from
U.S. products |
|
72.2% |
|
|
|
75.8% |
|
|
|
71.8% |
|
|
|
76.3% |
|
|
|
Add: non-cash excess and
obsolete charges |
|
8.4% |
|
|
|
1.7% |
|
|
|
8.5% |
|
|
|
3.2% |
|
|
|
Non-GAAP gross margin from
U.S. products |
|
80.6% |
|
|
|
77.5% |
|
|
|
80.3% |
|
|
|
79.5% |
|
|
|
|
|
|
|
|
|
|
|
|
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2024 to May 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From May 2023 to May 2024